![Head‐to‐head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences - Wan - 2019 - Journal of the European Academy of Dermatology and Venereology - Head‐to‐head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences - Wan - 2019 - Journal of the European Academy of Dermatology and Venereology -](https://onlinelibrary.wiley.com/cms/asset/f9bee270-494d-47c3-ab8a-bfa9cba8a948/jdv15174-fig-0002-m.jpg)
Head‐to‐head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences - Wan - 2019 - Journal of the European Academy of Dermatology and Venereology -
![Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials - Journal of the American Academy of Dermatology Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials - Journal of the American Academy of Dermatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/dcf78377-dd8a-4a53-b4a6-0c34b86e294a/gr1.jpg)
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials - Journal of the American Academy of Dermatology
![PDF] Clinical Trial Development of biologics for the Treatment of Psoriasis Developers are eyeing new therapeutic targets for biologic treatments for psoriasis | Semantic Scholar PDF] Clinical Trial Development of biologics for the Treatment of Psoriasis Developers are eyeing new therapeutic targets for biologic treatments for psoriasis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ffeeb75304a8b3fc8ea12a0628f68df105c3155e/2-Table1-1.png)
PDF] Clinical Trial Development of biologics for the Treatment of Psoriasis Developers are eyeing new therapeutic targets for biologic treatments for psoriasis | Semantic Scholar
![A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes - Journal of the American Academy of Dermatology A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes - Journal of the American Academy of Dermatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/64b969bc-2142-478a-9464-4e2a3de8c357/gr1.jpg)
A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes - Journal of the American Academy of Dermatology
![Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits – JCAD | The Journal of Clinical and Aesthetic Dermatology Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits – JCAD | The Journal of Clinical and Aesthetic Dermatology](https://jcadonline.com/wp-content/uploads/JCADJune2019GoldenbergTable1.gif)
Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits – JCAD | The Journal of Clinical and Aesthetic Dermatology
![Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator- controlled phase 3 trial - The Lancet Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator- controlled phase 3 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b843afb8-6390-4599-a869-52d0e3f1e194/gr1.jpg)